Two women plan to refile their suit against Ferring Pharmaceuticals Inc. alleging they lost opportunities for pregnancy and incurred expenses because of the company’s recalled fertility drug Bravelle, their attorney told Bloomberg BNA Jan. 13 (Bahalim v. Ferring Pharm., Inc., 2017 BL 9425, N.D. Ill., No. 16-8335, 1/12/17).
The U.S. District Court for the Northern District of Illinois dismissed the suit Jan. 12. The court said it lacked jurisdiction, or authority to hear the suit, because there wasn’t enough of a connection between Ferring and Illinois, where the case was filed.
The dismissal is “just a small bump ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.